JP2010530890A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010530890A5 JP2010530890A5 JP2010513435A JP2010513435A JP2010530890A5 JP 2010530890 A5 JP2010530890 A5 JP 2010530890A5 JP 2010513435 A JP2010513435 A JP 2010513435A JP 2010513435 A JP2010513435 A JP 2010513435A JP 2010530890 A5 JP2010530890 A5 JP 2010530890A5
- Authority
- JP
- Japan
- Prior art keywords
- compressed tablet
- sulfate
- lubricant
- compressed
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007891 compressed tablet Substances 0.000 claims 23
- 239000000314 lubricant Substances 0.000 claims 12
- YSIBYEBNVMDAPN-CMDGGOBGSA-N (e)-4-oxo-4-(3-triethoxysilylpropylamino)but-2-enoic acid Chemical compound CCO[Si](OCC)(OCC)CCCNC(=O)\C=C\C(O)=O YSIBYEBNVMDAPN-CMDGGOBGSA-N 0.000 claims 7
- 108010019625 Atazanavir Sulfate Proteins 0.000 claims 7
- 229960003796 atazanavir sulfate Drugs 0.000 claims 7
- 239000008187 granular material Substances 0.000 claims 6
- 229960000531 abacavir sulfate Drugs 0.000 claims 5
- WMHSRBZIJNQHKT-FFKFEZPRSA-N abacavir sulfate Chemical compound OS(O)(=O)=O.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 WMHSRBZIJNQHKT-FFKFEZPRSA-N 0.000 claims 5
- 229960001627 lamivudine Drugs 0.000 claims 5
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 5
- 238000005550 wet granulation Methods 0.000 claims 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 235000004443 Ricinus communis Nutrition 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- UGWQMIXVUBLMAH-IVVFTGHFSA-N [(1s,4r)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol;4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 UGWQMIXVUBLMAH-IVVFTGHFSA-N 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims 1
- 239000008116 calcium stearate Substances 0.000 claims 1
- 235000013539 calcium stearate Nutrition 0.000 claims 1
- 239000004203 carnauba wax Substances 0.000 claims 1
- 235000013869 carnauba wax Nutrition 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 1
- 229940075507 glyceryl monostearate Drugs 0.000 claims 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000002480 mineral oil Substances 0.000 claims 1
- 235000010446 mineral oil Nutrition 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 235000019198 oils Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims 1
- 235000010234 sodium benzoate Nutrition 0.000 claims 1
- 239000004299 sodium benzoate Substances 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94569107P | 2007-06-22 | 2007-06-22 | |
| PCT/US2008/067629 WO2009002826A2 (en) | 2007-06-22 | 2008-06-20 | Tableted compositions containing atazanavir |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010530890A JP2010530890A (ja) | 2010-09-16 |
| JP2010530890A5 true JP2010530890A5 (enExample) | 2011-07-21 |
Family
ID=39645379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010513435A Pending JP2010530890A (ja) | 2007-06-22 | 2008-06-20 | アタザナビルを含む錠剤組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20100178340A1 (enExample) |
| EP (1) | EP2178512B1 (enExample) |
| JP (1) | JP2010530890A (enExample) |
| KR (1) | KR20100033379A (enExample) |
| CN (1) | CN101778625A (enExample) |
| AT (1) | ATE500820T1 (enExample) |
| AU (1) | AU2008268630A1 (enExample) |
| DE (1) | DE602008005462D1 (enExample) |
| ES (1) | ES2359770T3 (enExample) |
| MX (1) | MX2009013499A (enExample) |
| WO (1) | WO2009002826A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10071059B2 (en) * | 2009-12-18 | 2018-09-11 | Frieslandcampina Nederland Holding B.V. | Co-processed tablet excipient composition its preparation and use |
| KR101317809B1 (ko) | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물 |
| WO2013057469A1 (en) * | 2011-10-20 | 2013-04-25 | Cipla Limited | Pharmaceutical antiretroviral compositions |
| US20140315936A1 (en) * | 2011-11-18 | 2014-10-23 | Avexa Limited | Apricitabine and pi combination therapy |
| KR20140096571A (ko) | 2013-01-28 | 2014-08-06 | 한미약품 주식회사 | 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2940998A (en) * | 1953-10-15 | 1960-06-14 | Ajinomoto Kk | Process for resolution of racemic glutamic acid and salts thereof |
| GB919491A (en) * | 1958-12-23 | 1963-02-27 | Ici Ltd | Pharmaceutical compositions |
| US4026897A (en) * | 1974-01-31 | 1977-05-31 | Otsuka Pharmaceutical Company | 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives |
| US3980637A (en) * | 1975-03-17 | 1976-09-14 | Bristol-Myers Company | Production of amoxicillin |
| US4556654A (en) * | 1983-06-28 | 1985-12-03 | Warner-Lambert Company | Antimicrobial substituted anthra[1,9-cd]pyrazol-6(2H)-ones |
| DE3403329A1 (de) * | 1984-02-01 | 1985-08-01 | Horst Dr. 4019 Monheim Zerbe | Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe |
| FR2623810B2 (fr) * | 1987-02-17 | 1992-01-24 | Sanofi Sa | Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant |
| US5158777A (en) * | 1990-02-16 | 1992-10-27 | E. R. Squibb & Sons, Inc. | Captopril formulation providing increased duration of activity |
| CA2068402C (en) * | 1991-06-14 | 1998-09-22 | Michael R. Hoy | Taste mask coatings for preparation of chewable pharmaceutical tablets |
| US5753652A (en) * | 1991-07-03 | 1998-05-19 | Novartis Corporation | Antiretroviral hydrazine derivatives |
| CA2103932A1 (en) * | 1992-11-05 | 1994-05-06 | Ramesh N. Patel | Stereoselective reduction of ketones |
| US5461067A (en) * | 1993-02-25 | 1995-10-24 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5428048A (en) * | 1993-11-08 | 1995-06-27 | American Home Products Corporation | Aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anto-arteriosclerotic agents |
| GB9407386D0 (en) * | 1994-04-14 | 1994-06-08 | Smithkline Beecham Plc | Pharmaceutical formulation |
| UA49803C2 (uk) * | 1994-06-03 | 2002-10-15 | Дж.Д. Сьорль Енд Ко | Спосіб лікування ретровірусних інфекцій |
| TW483763B (en) * | 1994-09-02 | 2002-04-21 | Astra Ab | Pharmaceutical composition comprising of ramipril and dihydropyridine compound |
| JP3529904B2 (ja) * | 1995-06-19 | 2004-05-24 | 鐘淵化学工業株式会社 | 光学活性1−ハロ−3−アミノ−4−フェニル−2−ブタノール誘導体の製造法 |
| US6037157A (en) * | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| US5750493A (en) * | 1995-08-30 | 1998-05-12 | Raymond F. Schinazi | Method to improve the biological and antiviral activity of protease inhibitors |
| US5767316A (en) * | 1995-11-17 | 1998-06-16 | Ajinomoto Co., Inc. | Process for producing 3-amino-2-oxo-1-halogenopropane derivatives |
| US5849911A (en) * | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
| US6087383A (en) * | 1998-01-20 | 2000-07-11 | Bristol-Myers Squibb Company | Bisulfate salt of HIV protease inhibitor |
| US6737264B1 (en) * | 1999-01-21 | 2004-05-18 | Kaneka Corporation | Method for purifying and isolating (2s,3s)- or (2r,3s)-halohydrin derivatives |
| EP1067125B1 (en) * | 1999-01-29 | 2006-07-26 | Kaneka Corporation | PROCESSES FOR THE PREPARATION OF threo-1,2-EPOXY-3-AMINO-4-PHENYLBUTANE DERIVATIVES |
| JP2002540102A (ja) * | 1999-03-22 | 2002-11-26 | ブリストル−マイヤーズ スクイブ カンパニー | cGMPホスホジエステラーゼの縮合ピリドピリダジン阻害剤 |
| US6605732B1 (en) * | 1999-05-03 | 2003-08-12 | Aerojet Fine Chemicals Llc | Clean, high-yield preparation of S,S and R,S amino acid isosteres |
| KR100708221B1 (ko) * | 1999-08-31 | 2007-04-17 | 아지노모토 가부시키가이샤 | 에폭사이드 결정의 제조방법 |
| US6399393B1 (en) * | 1999-09-21 | 2002-06-04 | The United States Of America As Represented By The Department Of Energy | Cryogenic homogenization and sampling of heterogeneous multi-phase feedstock |
| US6414002B1 (en) * | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| US6254888B1 (en) * | 2000-01-28 | 2001-07-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for coating pharmaceutical dosage forms |
| US6395767B2 (en) * | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| CZ20011726A3 (cs) * | 2000-05-26 | 2002-02-13 | Pfizer Products Inc. | Způsob reakční krystalizace, který umoľňuje řídit velikost částic |
| WO2002014528A1 (en) * | 2000-08-16 | 2002-02-21 | Bristol-Myers Squibb Company | Stereoselective reduction of substituted oxo-butanes |
| IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| US6670344B2 (en) * | 2000-09-14 | 2003-12-30 | Bristol-Myers Squibb Company | Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts |
| KR20020046948A (ko) * | 2000-12-12 | 2002-06-21 | 에가시라 구니오 | 에폭사이드 결정의 제조방법 |
| HRP20040181A2 (en) * | 2001-08-31 | 2004-08-31 | Bristol Myers Squibb Co | Use of atazanavir in hiv therapy |
| KR100933625B1 (ko) * | 2001-09-04 | 2009-12-24 | 다우 글로벌 테크놀로지스 인크. | 수성 에어 포움, 이를 사용한 고체 입자의 응집방법 및 피복방법 |
| US7384734B2 (en) * | 2002-02-15 | 2008-06-10 | Monogram Biosciences, Inc. | Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors |
| WO2003086319A2 (en) * | 2002-04-10 | 2003-10-23 | Merck & Co., Inc. | Pharmaceutical compositions containing an hiv integrase inhibitor and a nonionic surfactant |
| KR100456833B1 (ko) * | 2002-08-01 | 2004-11-10 | 주식회사 대웅 | 아목시실린 및 클라불라네이트를 함유하는 유핵정 |
| WO2004043433A2 (en) * | 2002-11-08 | 2004-05-27 | Glaxo Group Limited | Pharmaceutical antiviral compositions |
| US20050148523A1 (en) * | 2003-12-15 | 2005-07-07 | Colonno Richard J. | Method of treating HIV infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor |
| TW200534879A (en) * | 2004-03-25 | 2005-11-01 | Bristol Myers Squibb Co | Coated tablet formulation and method |
| US20050256314A1 (en) * | 2004-05-04 | 2005-11-17 | Soojin Kim | Process employing controlled crystallization in forming crystals of a pharmaceutical |
| US7829720B2 (en) * | 2004-05-04 | 2010-11-09 | Bristol-Myers Squibb Company | Process for preparing atazanavir bisulfate and novel forms |
| US20050288343A1 (en) * | 2004-05-19 | 2005-12-29 | Andrew Rusowicz | Process of preparing substituted carbamates and intermediates thereof |
| TWI415635B (zh) * | 2004-05-28 | 2013-11-21 | 必治妥施貴寶公司 | 加衣錠片調製物及製備彼之方法 |
| US7582468B2 (en) * | 2005-05-25 | 2009-09-01 | Bristol-Myers Squibb Company | Process for preparing (2R,3S)-1,2-epoxy-3-(protected)amino-4-substituted butane and intermediates thereof |
| US20070059360A1 (en) * | 2005-07-29 | 2007-03-15 | Ashish Jaiswal | Water-dispersible anti-retroviral pharmaceutical compositions |
| JP2010530888A (ja) * | 2007-06-22 | 2010-09-16 | ブリストル−マイヤーズ スクイブ カンパニー | アタザナビルを含む錠剤組成物 |
| JP2010530889A (ja) * | 2007-06-22 | 2010-09-16 | ブリストル−マイヤーズ スクイブ カンパニー | アタザナビルを含む錠剤組成物 |
| PT2178513E (pt) * | 2007-06-22 | 2011-05-31 | Bristol Myers Squibb Co | Composi??es em comprimido que cont?m atazanavir |
-
2008
- 2008-06-20 EP EP08771565A patent/EP2178512B1/en not_active Not-in-force
- 2008-06-20 KR KR1020097026606A patent/KR20100033379A/ko not_active Withdrawn
- 2008-06-20 MX MX2009013499A patent/MX2009013499A/es active IP Right Grant
- 2008-06-20 WO PCT/US2008/067629 patent/WO2009002826A2/en not_active Ceased
- 2008-06-20 DE DE602008005462T patent/DE602008005462D1/de active Active
- 2008-06-20 CN CN200880103691A patent/CN101778625A/zh active Pending
- 2008-06-20 US US12/664,806 patent/US20100178340A1/en not_active Abandoned
- 2008-06-20 JP JP2010513435A patent/JP2010530890A/ja active Pending
- 2008-06-20 AT AT08771565T patent/ATE500820T1/de not_active IP Right Cessation
- 2008-06-20 ES ES08771565T patent/ES2359770T3/es active Active
- 2008-06-20 AU AU2008268630A patent/AU2008268630A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010530889A5 (enExample) | ||
| JP2010530892A5 (enExample) | ||
| HRP20110294T1 (hr) | Smjese u obliku tablete koje sadržavaju atazanavir | |
| EA023807B1 (ru) | Устойчивые оральные фармацевтические дозированные формы, содержащие опиоидный анальгетик | |
| UY27995A1 (es) | Nuevas formulaciones farmacéuricas solidas que comprenden telmartisano y su preparación | |
| JP2010530890A5 (enExample) | ||
| HRP20161262T1 (hr) | Tablete ulipristal acetata | |
| JP2012197280A5 (enExample) | ||
| JP6301934B2 (ja) | チカグレロルを含む固形経口医薬製剤 | |
| JP2009526021A5 (enExample) | ||
| HRP20250604T1 (hr) | Formulacije tableta neratinib maleata | |
| JP2007523210A5 (enExample) | ||
| SI2821067T1 (en) | Quick spray formulation of cinacalcet | |
| JP2017525712A5 (enExample) | ||
| HRP20140146T1 (hr) | Smjese koje sadrže atazanavir oblikovane u tablete | |
| US20090317465A1 (en) | Composition and method of preparation of release systems for constant (zero-order) release of active agents | |
| WO2010020856A3 (en) | Rate modulated delivery of drugs from a composite delivery system | |
| JP2011525501A5 (enExample) | ||
| WO2007134158A3 (en) | Granules comprising calcium carbonate, a binder and a porosity increasing agent, processes of manufacturing, use in therapy | |
| JP5517327B2 (ja) | 口腔内崩壊錠用組成物 | |
| JP2019516674A5 (enExample) | ||
| JP2015521191A5 (enExample) | ||
| HRP20190550T1 (hr) | Formule i metode proizvodnje formulacija za upotrebu u pražnjenju debelog crijeva | |
| JP2008534522A5 (enExample) | ||
| JP2014530802A5 (enExample) |